AWM Investment Company Inc. Acquires New Shares in Abeona Therapeutics Inc. $ABEO

AWM Investment Company Inc. bought a new position in Abeona Therapeutics Inc. (NASDAQ:ABEO) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 470,000 shares of the biopharmaceutical company’s stock, valued at approximately $2,670,000. AWM Investment Company Inc. owned approximately 0.92% of Abeona Therapeutics at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of the business. Creative Planning boosted its position in shares of Abeona Therapeutics by 43.0% during the second quarter. Creative Planning now owns 14,310 shares of the biopharmaceutical company’s stock valued at $81,000 after buying an additional 4,305 shares during the last quarter. Ameritas Investment Partners Inc. bought a new position in Abeona Therapeutics during the 2nd quarter valued at about $25,000. Legal & General Group Plc purchased a new stake in shares of Abeona Therapeutics during the 2nd quarter valued at about $27,000. OMERS ADMINISTRATION Corp grew its stake in shares of Abeona Therapeutics by 11.0% in the first quarter. OMERS ADMINISTRATION Corp now owns 72,200 shares of the biopharmaceutical company’s stock worth $344,000 after acquiring an additional 7,155 shares during the period. Finally, Riverwater Partners LLC purchased a new position in shares of Abeona Therapeutics during the second quarter valued at approximately $62,000. Hedge funds and other institutional investors own 80.56% of the company’s stock.

Analyst Upgrades and Downgrades

ABEO has been the topic of several research reports. HC Wainwright restated a “buy” rating and issued a $20.00 target price on shares of Abeona Therapeutics in a report on Monday, October 13th. Weiss Ratings downgraded Abeona Therapeutics from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, October 24th. Oppenheimer lifted their price objective on Abeona Therapeutics from $19.00 to $20.00 and gave the stock an “outperform” rating in a report on Friday, August 15th. Finally, Wall Street Zen cut Abeona Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 15th. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Abeona Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $20.00.

Abeona Therapeutics Trading Down 2.9%

Shares of ABEO stock opened at $5.36 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 9.74 and a quick ratio of 9.53. The company has a market cap of $290.46 million, a price-to-earnings ratio of 4.36 and a beta of 1.12. Abeona Therapeutics Inc. has a 1 year low of $3.93 and a 1 year high of $7.54. The firm has a fifty day moving average price of $4.98 and a 200-day moving average price of $5.81.

Abeona Therapeutics (NASDAQ:ABEO) last released its earnings results on Wednesday, November 12th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.17. As a group, equities analysts predict that Abeona Therapeutics Inc. will post -1.16 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Mark Alvino sold 15,000 shares of Abeona Therapeutics stock in a transaction on Thursday, November 13th. The shares were sold at an average price of $4.74, for a total transaction of $71,100.00. Following the transaction, the director owned 62,252 shares in the company, valued at approximately $295,074.48. The trade was a 19.42% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Vishwas Seshadri sold 25,000 shares of the company’s stock in a transaction on Tuesday, September 30th. The stock was sold at an average price of $5.24, for a total transaction of $131,000.00. Following the completion of the transaction, the chief executive officer directly owned 1,190,067 shares of the company’s stock, valued at $6,235,951.08. This represents a 2.06% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 78,612 shares of company stock valued at $410,271 in the last 90 days. Corporate insiders own 6.90% of the company’s stock.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.